Contribute Try STAT+ Today

Over several months in 2017, a top Purdue Pharma executive and the head of the Addiction Policy Forum, a controversial patient advocacy group, discussed the possibility of working together to combat opioid addiction, according to emails reviewed by STAT.

One potential project concerned providing educational resources to people struggling with addiction issues, which the Addiction Policy Forum sought to launch. This occurred around the same time that the pharmaceutical industry trade group, PhRMA, was looking to its members — which included Purdue — to contribute to a multi-year, multi-million-dollar grant soon to be awarded to the advocacy group, the emails noted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment